News
SABS
4.010
-8.86%
-0.390
Weekly Report: what happened at SABS last week (0415-0419)?
Weekly Report · 3d ago
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 04/16 17:38
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
Benzinga · 04/16 17:28
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/16 11:52
SAB Biotherapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
Dow Jones · 04/16 11:52
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Benzinga · 04/16 11:41
SAB BIOTHERAPEUTICS: COMPLETED DOSING THIRD COHORT FOR SAB-142 WITH NO OBSERVATION OF SERUM SICKNESS THUS FAR
Reuters · 04/16 11:15
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness. SAB is developing human anti-thymocyte immunoglobulin for delaying onset or progression of type 1 diabetes (T1D) SAB Biotherapeutics, Inc. Is a clinical-stage biopharmaceutical company.
Barchart · 04/16 06:15
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
TipRanks · 04/15 21:33
SAB BIOTHERAPEUTICS: ON APRIL 12, COMPLETED DOSING OF COHORT 3 FOR PHASE ONE TRIALS OF SAB-142, HAS NOT OBSERVED ANY INSTANCES OF SERUM SICKNESSES
Reuters · 04/15 21:16
Weekly Report: what happened at SABS last week (0408-0412)?
Weekly Report · 04/15 11:14
Weekly Report: what happened at SABS last week (0401-0405)?
Weekly Report · 04/08 11:19
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics will be featured as a key partner at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024. SAB is developing a novel immunotherapy platform for delaying the onset or progression of type 1 diabetes. Chief Medical Officer will share an overview of the SAB-142 clinical development plan.
Barchart · 04/08 06:15
SAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy Rating
TipRanks · 04/04 06:35
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
SAB Biotherapeutics, Inc. Will present an overview of the company at the 23rd Annual Needham Virtual Conference on April 11, 2024. The company is developing a novel immunotherapy platform for delaying the onset or progression of type 1 diabetes. Samuel J. Reich, the company's Chairman and CEO, will present.
Barchart · 04/04 06:15
SAB Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
SAB Biotherapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $3.38 per share. Revenue was $305.00 thousand; analysts expected zero. SAB shares have fallen by 5.5% this quarter and 37.6% this year.
Reuters · 04/02 22:47
SAB Biotherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/02 13:28
Chardan Capital Maintains Buy on SAB Biotherapeutics, Adjusts Price Target To $25 (reverse stock split 1:10)
Benzinga · 04/02 13:17
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 12:50
SAB Biotherapeutics Price Target Cut to $6.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 04/02 12:50
More
Webull provides a variety of real-time SABS stock news. You can receive the latest news about SAB BIOTHERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.